Our data suggested that the sensitivity of ccRCC cell lines to the BIRC5-targeted drug, Sepantronium bromide, was significantly higher than the sensitivity to conventional targeted drugs (Figure 10A–10C; Table 3; p < 0.05). Here, BIRC5 is linked to nonpapillary renal cell carcinoma.